Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 200 of 1515 results for patients and public

  1. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development Reference number: GID-TA11484 Expected publication date: TBC

  2. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

    In development Reference number: GID-TA11373 Expected publication date: TBC

  3. Type 2 diabetes: prevention in people at high risk (PH38)

    This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .

  4. Photodynamic therapy for localised inoperable endobronchial cancer (HTG85)

    Evidence-based recommendations on photodynamic therapy (PDT) for localised inoperable endobronchial cancer (non-small-cell lung cancer). This involves injecting a photosensitising agent into the body that is activated by laser light to destroy the cancerous tissue.

  5. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development Reference number: GID-TA11091 Expected publication date:  22 April 2026

  6. Medical technologies advisory committee members

    Read the biographies of our medical technologies advisory committee members.

  7. Mental wellbeing of older people in care homes (QS50)

    This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.

  8. Percutaneous endoscopic colostomy (HTG105)

    Evidence-based recommendations on percutaneous endoscopic colostomy. This involves placing a plastic tube in the bowel that runs back through a small opening in the abdomen to allow waste to pass through to a drainage bag worn outside the body.

  9. Blood transfusion (NG24)

    This guideline covers the assessment for and management of blood transfusions in adults, young people and children over 1 year old. It covers the general principles of blood transfusion, but does not make recommendations relating to specific conditions.

  10. Making a positive impact: people and communities network case studies

    Making a positive impact: NICE people and communities network case studies

  11. Making a positive impact: people and communities network case studies

    Making a positive impact: NICE people and communities network case studies

  12. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia

    Awaiting development Reference number: GID-MT599 Expected publication date: TBC

  13. Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

    In development Reference number: GID-TA10024 Expected publication date:  28 June 2017

  14. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

    In development Reference number: GID-TA11519 Expected publication date:  12 June 2026

  15. HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)

    This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.

  16. Clostridioides difficile infection: antimicrobial prescribing (NG199)

    This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.

  17. Cyanoacrylate instillation for occlusion of parotid sinuses (HTG20)

    Evidence-based recommendations on cyanoacrylate instillation for occlusion of parotid sinuses. This involves injecting a solution of lipiodiol and cyanoacrylate via the sinus into the parotid gland, sealing the sinus.

  18. Appeal panel membership

    The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.

  19. Vaccine uptake in the general population (NG218)

    This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.

  20. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTE10069 Expected publication date:  11 August 2026

  21. Intravenous fluid therapy in adults in hospital (CG174)

    This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.

  22. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development Reference number: GID-TA11096 Expected publication date: TBC

  23. Technology appraisal committee C members

    Biographies and registered interests for members of the Technology Appraisal Committee C

  24. Insertion of hydrogel keratoprosthesis (HTG42)

    Evidence-based recommendations on insertion of hydrogel keratoprosthesis. This involves putting an artificial cornea into place in a pocket made in the front part of the eye.

  25. NICE indicator process guide (PMG44)

    This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance or other sources of high-quality evidence

  26. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  27. Service user experience in adult mental health: improving the experience of care for people using adult NHS mental health services (CG136)

    This guideline covers the components of a good experience of service use. It aims to make sure that all adults using NHS mental health services have the best possible experience of care.

  28. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development Reference number: GID-TA11023 Expected publication date: TBC

  29. Structure of NICE

    same mission: helping practitioners and commissioners get the best care to patients fast, while ensuring value for the taxpayer. To...

  30. Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

  31. Vagus nerve stimulation for refractory epilepsy in children (HTG25)

    Evidence-based recommendations on vagus nerve stimulation for refractory epilepsy in children. This involves placing a device under the skin to send a burst of nerve messages through the nerve.

  32. Sexual health (QS178)

    This quality standard covers sexual health, focusing on preventing sexually transmitted infections (STIs). It describes high-quality care in priority areas for improvement.

  33. High dose rate brachytherapy for carcinoma of the cervix (HTG104)

    Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.

  34. Oesophago-gastric cancer: assessment and management in adults (NG83)

    This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.

  35. Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.

  36. Balloon angioplasty of pulmonary vein stenosis in infants (HTG46)

    Evidence-based recommendations on balloon angioplasty of pulmonary vein stenosis in infants. This involves involves inflating a balloon in the narrow section of the pulmonary vein to widen the area so blood can flow through more easily.

  37. Oral health for adults in care homes (NG48)

    This guideline covers oral health, including dental health and daily mouth care, for adults in care homes. The aim is to maintain and improve their oral health and ensure timely access to dental treatment.

  38. Fallopian tube recanalisation by guidewire (HTG44)

    Evidence-based recommendations on fallopian tube recanalisation by guidewire. This involves injecting dye through a narrow tube inserted into the fallopian tube and if this does not unblock it, using a guidewire.

  39. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  13 May 2026

  40. Getting involved as someone with lived experience

    We want you to help NICE to develop our guidance for NHS and care services.

  41. Getting involved as someone with lived experience

    We want you to help NICE to develop our guidance for NHS and care services.

  42. Technology appraisal committee C members

    Biographies and registered interests for members of the Technology Appraisal Committee C

  43. Lumbar subcutaneous shunt (HTG41)

    Evidence-based recommendations on lumbar subcutaneous shunt. This involves using a shunt to drain excess cerebrospinal fluid away so that it doesn’t damage the brain or eyes.

  44. Technology appraisal committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  45. Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.

  46. Surgical site infection (QS49)

    This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.

  47. Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)

    This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs

  48. About interventional procedures guidance

    We assess the efficacy and safety of interventional procedures used for treatment or diagnosis to determine whether they work well enough and are safe enough for use in the NHS.

  49. What lay members do

    guidance Adoption and impact reference panel membership Meetings in public Consultations GPs and primary care NICE training and...

  50. What lay members do

    guidance Adoption and impact reference panel membership Meetings in public Consultations GPs and primary care NICE training and...